Tumor immune microenvironment alterations using induction cetuximab in a phase II trial of deintensified therapy for p16-positive oropharynx cancer.
Joshua D SmithMegan L LudwigApurva D BhangaleCollin BrummelPaul L SwiecickiFrancis P WordenSteven B ChinnChaz L StuckenAndrew J RoskoMark E P PrinceKelly M MalloyKeith A CasperCarol R BradfordDouglas B ChepehaJennifer ShahCaitlin A SchonewolfJonathon B McHughMukesh K NyatiAvraham EisbruchMichelle L MierzwaMatthew E SpectorJohn Chad BrennerPublished in: Head & neck (2023)
Within 1 week, cetuximab induced measurable changes in pro-cytotoxic T-cell signaling and immune content.